



Press release

SORIN GROUP AND GREATBATCH ANNOUNCE COLLABORATIVE AGREEMENT TO LEVERAGE GREATBATCH'S MRI TECHNOLOGY FOR SORIN GROUP CRM DEVICES

Clarence, N.Y. (USA) – May 16, 2008 - The Sorin Group and Greatbatch announced today the execution of a letter of intent that will leverage Greatbatch's eM-able(TM) technology in the Sorin Group's future cardiac rhythm management (CRM) systems.

Catherine Picard, vice-president of R&D at Sorin Group said, "We are very excited by the opportunity to leverage Greatbatch's eM-able(TM) technology to accelerate our MRI program and deliver MRI conditional systems to patients and physicians worldwide in the shortest possible time."

Many patients implanted with a pacemaker or a defibrillator (ICD) cannot take advantage of an MRI scan, because energy from this life-saving technology can change how a device controls the heart, damages the device or injures the heart tissue surrounding it.

MRI conditional approved devices are critical to allow patients with active implantable medical devices (AIMDs) to safely have an MRI for diagnostic evaluation.

"As we see more patients receive AIMD's the need for MRI conditional devices will continue to grow, said Mauricio Arellano, senior vice president of Greatbatch's CRM & Neuromodulation business. "This potential partnership with Sorin Group would meet that demand by securing our technology in their next generation devices."

John Farrell, vice-president of Greatbatch's Therapy Delivery business, added, "There has been extensive research and technology development on eM-able(TM), and we are excited to get moving on our first commercialization program that will bring the technology to market, improving patient safety."

About eM-able(TM)

eM-able(TM) technology can be incorporated into implantable devices to enhance safety for patients during MRI scans. Recently issued patent 7,363,090 by the U.S. Patent and Trademark Office, eM-able(TM) utilizes the technology of a band stop filter to attenuate frequency during an MRI and eliminate heating of electrodes within an implanted stimulation system.

For additional information go to <http://www.greatbatch.com/Medical/technologies.aspx>

About Sorin Group

The Sorin Group (Bloomberg: SRN.IM; Reuters: SORN.MI), a world leader in the development of medical technologies for cardiac surgery, offers innovative therapies for cardiac rhythm dysfunctions, interventional cardiology and the treatment of chronic kidney diseases. The Sorin Group includes these brands: Dideco, CarboMedics, COBE Cardiovascular, Stockert, Mitroflow, ELA Medical, Sorin Biomedica, Bellco and Bellco-Soludia. At the Sorin Group 4,500 employees work to serve over 5,000 public and private treatment centers in more than 80 countries throughout the world. For more information, please visit: www.sorin.com.

About Greatbatch, Inc.

Greatbatch, Inc. (NYSE: GB) is a leading developer and manufacturer of critical products used in implantable medical devices for the cardiac rhythm management, neuromodulation, vascular and orthopedic markets. Additionally, Electrochem, a subsidiary of Greatbatch, is a world leader in the design and manufacture of technology solutions for some of the world's most demanding and extreme applications. Additional information about the Company is available at www.greatbatch.com.

CONTACTS

Greatbatch

Investor Relations

Marco Benedetti, 716-759-5856

MBenedetti@greatbatch.com

or

Media

Kathryn Tarquin, 716-937-5222

KTarquin@greatbatch.com

Sorin Group

Martine Konorski

Director, Corporate Communications

Tel: +33 (0)1 46 01 33 78 / (Italy) +39-02-438114206

martine.konorski@sorin.com